Non-Small Cell Lung Carcinoma – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23109IDB-L5

Select Item

Empower your strategies with our Non-Small Cell Lung Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions.

Non-small cell lung carcinoma (NSCLC) is the most common type of lung cancer. “Non-small cell” refers to the way cancer cells look under a microscope. If the cells look small, the cancer is referred to as small cell lung cancer (SCLC). According to the American Cancer Society, about 80 to 85 percentTrusted Source of all lung carcinomas fall into the non-small cell category. NSCLC doesn’t tend to spread as fast as SCLC and has a better survival rate.

The Non-Small Cell Lung Carcinoma drugs in development market research report provide comprehensive information on the therapeutics under development for Non-Small Cell Lung Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non-Small Cell Lung Carcinoma and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Non-Small Cell Lung Carcinoma
Key Targets
· Programmed Cell Death Protein 1; Epidermal Growth Factor Receptor ERB1; ALK Tyrosine Kinase Receptor; Cytotoxic T Lymphocyte Protein 4; Programmed Cell Death 1 Ligand 1; Hepatitis A Virus Cellular Receptor 2 ; Serine/Threonine Protein Kinase mTOR; Receptor Tyrosine Protein Kinase ERBB 3; Mast/Stem Cell Growth Factor Receptor Kit; and Vascular Endothelial Growth Factor Receptor
Key Mechanisms of Action
· Programmed Cell Death Protein 1 Antagonist; Serine/Threonine Protein Kinase mTOR Inhibitor; Hepatitis A Virus Cellular Receptor 2 Inhibitor; Epidermal Growth Factor Receptor ERB1 Inhibitor; Leukocyte Surface Antigen CD47 Inhibitor; Mast/Stem Cell Growth Factor Receptor Kit Inhibitor; Cytotoxic T Lymphocyte Protein 4 Antagonist; Receptor Tyrosine Protein Kinase ERBB 3 Antagonist; Programmed Cell Death 1 Ligand 1 Inhibitor; and Platelet Derived Growth Factor Receptor Inhibitor
Key Routes of Administration
· Intravenous; Oral; Subcutaneous; Parenteral; Intravenous Drip; Intraperitoneal; Intralesional; Intramuscular; Intradermal; and Intra-abdominal
Key Molecule Types
· Small Molecule; Monoclonal Antibody; Gene-Modified Cell Therapy; Fusion Protein; Cell Therapy; Monoclonal Antibody Conjugated; Subunit Vaccine; Synthetic Peptide; mRNA Vaccine; and Peptide
Major Companies
· Xiangxue Life Sciences; AstraZeneca Plc; U.S. National Institutes of Health; Pfizer Inc; Agency for Science, Technology and Research; Bristol-Myers Squibb Co; GSK plc; Harbour BioMed (Guangzhou) Co Ltd; FUDAN University; and Galera Therapeutics Inc

Scope

  • Therapeutics in Development: Covering 89 molecules, with 80 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Non-Small Cell Lung Carcinoma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Non-Small Cell Lung Carcinoma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Non-Small Cell Lung Carcinoma treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

AbbVie Inc
Accendatech Co Ltd
Adagene Suzhou Ltd
Adaptimmune Therapeutics Plc
Agency for Science
Technology and Research
Akeso Inc
amcure GmbH
Amgen Inc
Andarix Pharmaceuticals Inc
Antengene Corp Ltd
Asher Biotherapeutics Inc
Astellas Pharma Inc
AstraZeneca Plc
BeiGene Ltd
Biomica Ltd
Boehringer Ingelheim International GmbH
BridgeBio Pharma Inc
Bristol-Myers Squibb Co
CARsgen Therapeutics Ltd
CDR-Life Inc
Coherus BioSciences Inc
Convalife
CSPC Pharmaceutical Group Ltd
Eli Lilly and Co
FUDAN University
Galera Therapeutics Inc
GenFleet Therapeutics (Shanghai) Inc
GSK plc
Harbour BioMed (Guangzhou) Co Ltd
HK inno.N Corp
Humanetics Corp
Hummingbird Bioscience Pte Ltd
Icahn School of Medicine at Mount Sinai
Immatics NV
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Immutep Ltd
InnoPharmaScreen Inc
Instil Bio Inc
Invectys SA
Ipsen SA
J2H Biotech
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Komipharm International Co Ltd
Laekna Therapeutics Shanghai Co Ltd
Les Laboratoires Servier SAS
Likang Life Sciences Holdings Ltd
Mabpro as
Metagone Biotech Inc
Minneamrita Therapeutics LLC
Moderna Inc
MOYA Bio
National Cancer Institute US
Nippon Kayaku Co Ltd
Ocean Biomedical Inc.
pacDNA LLC
Pfizer Inc
Ribon Therapeutics Inc
Sagimet Biosciences Inc
Shanghai Junshi Biosciences Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Sichuan Huiyang Life Science and Technology Corp
SK Biopharmaceuticals Co Ltd
Suzhou Maximum Bio-tech Co Ltd
Systimmune Inc
Taiwan Liposome Co Ltd
The First Affiliated Hospital of the University of Science and Technology of China
Torqur AG
Turgut Ilaclari AS
U.S. National Institutes of Health
Valo Health LLC
WellMarker Bio Co Ltd
Wuhan YZY Biopharma Co Ltd
Xencor Inc
Xiangxue Life Sciences
Y-Biologics Inc
Zhuhai Beihai Biotech Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Non-Small Cell Lung Carcinoma reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Non-Small Cell Lung Carcinoma – Drugs In Development, 2024 in real time.

  • Access a live Non-Small Cell Lung Carcinoma – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more